Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | CPB1 | P15086 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.42 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20334501 | 0.89 | ADRA1A (0.48) | ALDH1A1FKBP1AUSP2KMT2A | |
| SCHEMBL24434796 | 0.83 | KMT2A (0.57) | ALDH1A1FKBP1AHDAC1HDAC6ITGB1 | |
| SCHEMBL2583749 | 0.83 | KMT2A (0.57) | ALDH1A1FKBP1AHDAC1HDAC6ITGB1 | |
| SCHEMBL927807 | 0.83 | KMT2A (0.57) | ALDH1A1FKBP1AHDAC1HDAC6ITGB1 | |
| SCHEMBL29816738 | 0.81 | KMT2A (0.49) | FKBP1ACPB1KMT2AHTTNPC1 | |
| SCHEMBL20886535 | 0.81 | KMT2A (0.49) | FKBP1ACPB1KMT2AHTTNPC1 | |
| SCHEMBL19313922 | 0.81 | KMT2A (0.49) | FKBP1ACPB1KMT2AHTTNPC1 | |
| SCHEMBL5741011 | 0.80 | KMT2A (0.54) | ALDH1A1FKBP1AHDAC1HDAC6ITGB1 | |
| SCHEMBL19975250 | 0.80 | ALDH1A1 (0.66) | ALDH1A1FKBP1AUSP2KMT2ARAB9A | |
| SCHEMBL21869824 | 0.80 | FKBP1A (0.53) | FKBP1AHDAC1HDAC6ITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200277259-A1 | BETA-HYDROXY HETEROCYCLIC AMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2020-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200277259-A1 | BETA-HYDROXY HETEROCYCLIC AMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | SLC5A1, GPR119, SLC5A2 | ALDH1A1 229/4885FKBP1A 4003/4885HDAC1 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.